Pentokey Organy Q1 Results: Net Profit Falls 55% To ₹21.73 Lakh
Pentokey Organy's Q1FY27 results show a 55% YoY profit decline to ₹21.73 lakh amid zero operational revenue. Other income rose to ₹8.34 lakh, while negative expenses of ₹13.39 lakh supported the bottom line. Full-year FY26 profit was ₹20.32 lakh.
*this image is generated using AI for illustrative purposes only.
Pentokey Organy (India) Limited reported a net profit of ₹21.73 lakh for the quarter ended June 30, 2026, marking a significant decline from the ₹48.47 lakh posted in the corresponding period of FY25. The Mumbai-based pharma and pesticides trading firm recorded zero revenue from operations for the quarter, a sharp contrast to the ₹506.20 lakh generated in Q1FY26.
The Board of Directors approved the unaudited financial results in a meeting held on August 13, 2026. The figures were reviewed by the Audit Committee and subsequently approved by the Board, which convened from 12:30 pm to 1:10 pm.
Financial Performance
Despite the absence of operational revenue, the company remained profitable due to other income and lower expenses compared to the prior year. Other income stood at ₹8.34 lakh, up from ₹4.00 lakh in Q1FY25. Total expenses for the quarter were negative ₹13.39 lakh, primarily driven by a credit entry of ₹17.69 lakh under "Others Expenses," offset by employee benefit expenses of ₹4.30 lakh.
| Metric | Q1FY27 (₹ Lakh) | Q1FY26 (₹ Lakh) | Change |
|---|---|---|---|
| Revenue from Operations | - | 506.20 | N/A |
| Other Income | 8.34 | 4.00 | +108.5% |
| Total Expenses | (13.39) | 461.73 | N/A |
| Net Profit | 21.73 | 48.47 | -55.2% |
For the full year ended March 31, 2026, Pentokey Organy reported a net profit of ₹20.32 lakh on total income of ₹249.80 lakh, compared to a profit of ₹24.55 lakh on income of ₹129.05 lakh in FY25.
What the Numbers Show
The divergence between revenue and profitability highlights a structural shift in the company's earnings mix for the quarter. With revenue from operations at zero, other income accounted for 100% of the top-line inflow, while the negative expense figure suggests significant non-cash credits or reversals in the "Others Expenses" category. This indicates that the reported net profit is not derived from core trading activities in the pharma/pesticides segment but rather from incidental gains and expense adjustments.
Auditor Review
Verma Mehta & Associates, the statutory auditors, issued an unmodified review report on the interim financial results. The audit firm stated that nothing came to their attention to cause them to believe the statement had not been prepared in accordance with Ind AS and SEBI Listing Regulations. The results have been prepared in compliance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013.
Historical Stock Returns for Pentokey Organy
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.55% | -12.51% | -9.29% | -12.51% | -26.23% | +61.42% |
What strategic initiatives is Pentokey Organy pursuing to restore operational revenue in the pharma and pesticides trading segments for the upcoming quarters?
How sustainable is the current profitability model given that net profit is now derived entirely from other income and expense adjustments rather than core operations?
What specific factors contributed to the significant negative total expenses in Q1FY27, and will these credit entries recur in future periods?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
